Business Context and Reporting Period
This Form 8-K Current Report, dated September 16, 2024, details a strategic partnership and capital raise by Capricor Therapeutics, Inc. (Capricor). The filing announces a Binding Term Sheet with Nippon Shinyaku, Co., Ltd. for the commercialization of Capricor's lead product candidate, deramiocel, for the treatment of Duchenne muscular dystrophy in the European region.
Key Financial Metrics and Transaction Details
- Private Placement Proceeds: Capricor sold 2,798,507 shares of common stock to Nippon Shinyaku for an aggregate purchase price of approximately $15.0 million.
- Share Price: The shares were issued at $5.36 per share, representing a 20% premium to the 60-day volume-weighted average price (VWAP) through September 16, 2024.
- Upfront Payment: Capricor is scheduled to receive an upfront payment of $20.0 million upon execution of the Definitive Agreement.
- Milestone Payments: Potential additional development and sales-based milestone payments total up to $715.0 million.
- Revenue Share: Capricor will receive a double-digit share of product revenue from Nippon Shinyaku.
- Liquidity and Debt: The filing does not provide specific data on total cash balances, debt levels, or operating cash flow as of the reporting date.
Material Changes and Agreements
The primary material change is the entry into a Commercialization and Distribution Binding Term Sheet. Under this agreement, Capricor retains responsibility for development and manufacturing of deramiocel for the European region, while Nippon Shinyaku assumes responsibility for sales and distribution. Additionally, the company amended a Common Stock Purchase Warrant issued to Nippon Shinyaku in September 2023, restricting exercise rights to prevent Nippon Shinyaku from owning more than 19.99% of the company's outstanding shares.
Outlook, Risks, and Contingencies
- Definitive Agreement: The commercialization terms are subject to the finalization of a Definitive Agreement. The Term Sheet is expected to be filed as an exhibit to the Form 10-Q for the period ended September 30, 2024.
- Lock-Up Provisions: Nippon Shinyaku is restricted from selling or disposing of the acquired shares until the six-month anniversary of the closing date.
- Registration Rights: Capricor is obligated to file a registration statement with the SEC to register the shares for resale as soon as practicable.
- Confidentiality: The company intends to seek confidential treatment for certain terms and provisions of the Term Sheet.
Key Facts for Investor Verification
- Verify the final terms of the Definitive Agreement once executed, specifically regarding the exact revenue share percentage and milestone triggers.
- Confirm the closing date and receipt of the $15.0 million private placement proceeds and the $20.0 million upfront payment.
- Monitor the filing of the Registration Statement for the resale of shares by Nippon Shinyaku.
- Review the upcoming Form 10-Q for the full text of the Term Sheet and any confidential treatment requests.
- Assess the impact of the 19.99% ownership cap on Nippon Shinyaku's future warrant exercises.